iBio Inc (IBIO)

[JPetroInc]

from Stockwit's: Why would Tom Isett tweet a picture of NVAX's COVID-19 vaccines that are kept in a tray at NVAX's labs in Maryland on March 20th? NVAX vaccine requires an immune-boosting ingredient called an 'adjuvant' to be effective.



NPR coverage here on NVAX COVID-19 vaccine work:

The Special Sauce That Makes Some Vaccines Work

August 6, 20202:29 PM ET

https://www.npr.org/sections/health-shots/2020/08/06/899813217/the-special-sauce-that-makes-some-vaccines-work?utm_campaign=storyshare&utm_source=twitter.com&utm_medium=social

____________________________________________________________

Note: Dr Corey Casper from Infectious Disease Research Institute (IDRI) is quoted in same article above...

https://www.streetinsider.com/dr/news.php?id=16727405

That's a sentiment Corey Casper totally agrees with. He's the CEO of the Infectious Disease Research Institute and a proselytizer for adjuvant research. Casper says to consider what happened when the pharmaceutical company GlaxoSmithKline added a powerful adjuvant to a shingles vaccine.

"It took a vaccine that had previously existed which was about 50% effective, and it made it 97% effective," Casper says. "Not just in all people but in the hardest-to-protect people, which are the elderly, who typically make poor immune responses."

Casper says the vaccine community has underestimated the importance of adjuvants. He even has data suggesting that adjuvants alone might be capable of preventing infectious disease. That has enormous implications.

"Every time a new infection pops up, there's a race to develop a new vaccine for it," Casper says. "But what if you could give the adjuvant alone and you didn't have to develop a vaccine? That adjuvant could be stockpiled, it could be made at millions of doses, placed on the shelf, sitting there waiting for the next pandemic.

______________________________________________________________

Is IBIO and NVAX working together behind the scenes…?